Valeo Financial Advisors’s Novavax NVAX Stock Holding History

Valeo Financial Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-200	Closed	-$36K	–	1364
2021 Q1	$36K	Buy	+200	New	+$39.9K	﹤0.01%	987

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Valeo Financial Advisors's NVAX Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Novavax (NVAX) in Q2 2021, closing a stake of 42 shares — an estimated $8K sold.

Valeo Financial Advisors first reported a position in NVAX in Q2 2020 and held it in 3 quarters. The position peaked at $8K in Q1 2021. 407 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

Valeo Financial Advisors reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
Valeo Financial Advisors sold 42 Novavax shares in Q2 2021, an estimated $8K.
Valeo Financial Advisors first reported a position in Novavax in Q2 2020 and held it in 3 quarters.
Valeo Financial Advisors's Novavax position peaked at $8K in Q1 2021.
407 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.